HK1042425B - 增加含cg模體的寡核酸甘酸的奈瑟氏菌抗原的殺菌活動 - Google Patents

增加含cg模體的寡核酸甘酸的奈瑟氏菌抗原的殺菌活動

Info

Publication number
HK1042425B
HK1042425B HK02102264.3A HK02102264A HK1042425B HK 1042425 B HK1042425 B HK 1042425B HK 02102264 A HK02102264 A HK 02102264A HK 1042425 B HK1042425 B HK 1042425B
Authority
HK
Hong Kong
Prior art keywords
motifs
enhancement
bactericidal activity
oligonucleotides containing
adjuvant
Prior art date
Application number
HK02102264.3A
Other languages
English (en)
Other versions
HK1042425A1 (en
Inventor
Grandi Guido
Rappuoli Rino
Monica Giuliani Marzia
Pizza Mariagrazia
Original Assignee
Novartis Vaccines And Diagnostics S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics S R L filed Critical Novartis Vaccines And Diagnostics S R L
Publication of HK1042425A1 publication Critical patent/HK1042425A1/xx
Publication of HK1042425B publication Critical patent/HK1042425B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HK02102264.3A 1999-02-26 2002-03-25 增加含cg模體的寡核酸甘酸的奈瑟氏菌抗原的殺菌活動 HK1042425B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12179299P 1999-02-26 1999-02-26
PCT/IB2000/000176 WO2000050075A2 (en) 1999-02-26 2000-02-09 Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs

Publications (2)

Publication Number Publication Date
HK1042425A1 HK1042425A1 (en) 2002-08-16
HK1042425B true HK1042425B (zh) 2005-04-01

Family

ID=22398817

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102264.3A HK1042425B (zh) 1999-02-26 2002-03-25 增加含cg模體的寡核酸甘酸的奈瑟氏菌抗原的殺菌活動

Country Status (11)

Country Link
US (1) US8221761B1 (zh)
EP (1) EP1154790B1 (zh)
JP (2) JP4812942B2 (zh)
AT (1) ATE279943T1 (zh)
AU (1) AU2457100A (zh)
CA (1) CA2371994C (zh)
DE (1) DE60015084T2 (zh)
ES (1) ES2228454T3 (zh)
HK (1) HK1042425B (zh)
PT (1) PT1154790E (zh)
WO (1) WO2000050075A2 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP2278007B1 (en) 1999-04-30 2014-04-16 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
CA2373236C (en) 1999-05-19 2014-08-26 Chiron S.P.A. Combination neisserial compositions
DK1741784T3 (da) * 1999-11-29 2010-05-25 Novartis Vaccines & Diagnostic 85kDa-antigen fra neisseria
DK1947187T5 (da) 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
AU2002252638A1 (en) 2001-04-17 2002-10-28 Children's Hospital Oakland Research Institute Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
NZ532274A (en) * 2001-10-03 2006-02-24 Chiron Corp Adjuvanted meningococcus compositions
JP2005508945A (ja) * 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP2575773A4 (en) 2010-05-26 2014-06-25 Selecta Biosciences Inc SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
EP1005368B1 (en) * 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
PT1047784E (pt) * 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261346A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9810276D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9820003D0 (en) * 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
GB9826886D0 (en) * 1998-12-07 1999-01-27 Smithkline Beecham Biolog Novel compounds
US6797273B1 (en) * 1999-01-15 2004-09-28 Glaxosmithkline Biologicals S.A. Neisseria meningitidis antigen
CN1375006A (zh) * 1999-01-22 2002-10-16 史密丝克莱恩比彻姆生物有限公司 新型化合物
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
TR200103018T2 (tr) * 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
EP2278007B1 (en) * 1999-04-30 2014-04-16 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK1897555T3 (da) * 2000-01-17 2014-10-13 Novartis Vaccines & Diagnostic Kompletteret OMV-vaccine mod meningococcus
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
DK1947187T5 (da) * 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
US20040258702A1 (en) * 2000-06-22 2004-12-23 Blonder Joan P. Vaccine delivery
US7767197B2 (en) * 2000-06-22 2010-08-03 Endo Pharmaceuticals Colorado LLC Delivery vehicle composition and methods for delivering antigens and other drugs
JP2004518631A (ja) * 2000-09-28 2004-06-24 カイロン コーポレイション 異種核酸の送達のための微粒子
MXPA03002643A (es) * 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
AU2002252638A1 (en) * 2001-04-17 2002-10-28 Children's Hospital Oakland Research Institute Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
US6541554B2 (en) * 2001-05-17 2003-04-01 Milliken & Company Low-shrink polypropylene fibers
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US7838015B2 (en) * 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
EP1585542B1 (en) * 2002-12-27 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
JP2007516219A (ja) * 2003-05-07 2007-06-21 アヴェンティス パストゥール インコーポレイテッド 髄膜炎菌ワクチン接種に対する免疫原性の増強の方法
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
US7615539B2 (en) * 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
GB0401239D0 (en) * 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
KR100721928B1 (ko) * 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
EP1858920B1 (en) * 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CA2601022C (en) * 2005-03-23 2023-03-07 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
CA2664619C (en) * 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
US20090089165A1 (en) * 2007-09-28 2009-04-02 Embarq Holdings Company, Llc System and method for a telephony upgrade credit

Also Published As

Publication number Publication date
DE60015084T2 (de) 2006-02-16
WO2000050075A2 (en) 2000-08-31
CA2371994A1 (en) 2000-08-31
HK1042425A1 (en) 2002-08-16
AU2457100A (en) 2000-09-14
JP2010174044A (ja) 2010-08-12
PT1154790E (pt) 2005-03-31
JP2002537353A (ja) 2002-11-05
ES2228454T3 (es) 2005-04-16
EP1154790B1 (en) 2004-10-20
EP1154790A2 (en) 2001-11-21
ATE279943T1 (de) 2004-11-15
US8221761B1 (en) 2012-07-17
CA2371994C (en) 2010-09-28
JP4812942B2 (ja) 2011-11-09
DE60015084D1 (de) 2004-11-25
WO2000050075A3 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
HK1042425B (zh) 增加含cg模體的寡核酸甘酸的奈瑟氏菌抗原的殺菌活動
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
EP2277539A3 (en) Neisseria meningitidis conjugate combination vaccine
PT1235589E (pt) Composições compreendendo antigénios da neisseria meningitidis dos serogrupos b e c, e outro antigénio
EP2172213A3 (en) Injectable vaccines against multiple meningococcal serogroups
EP1955709A3 (en) Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
GB9817052D0 (en) Vaccine
WO2003094834A3 (en) Mucosal vaccines with chitosan adjuvant and meningococcal antigens
BR0015961A (pt) Antìgeno de neisseria de 85kda
EP1379272A4 (en) MOLECULAR MIMETICS OF MENINGOKOKEN B EPITOPES THAT MAKE THE FORMATION OF FUNCTIONALLY EFFECTIVE ANTIBODIES
GB0129007D0 (en) Adjuvanted antigenic meningococcal compositions
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
EP2364726A3 (en) Vaccine against neisseria infection
WO2004097000A3 (en) Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions
ZA200108619B (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130209